PNEUMOCOCCAL VACCINE VACCINATION IN CHILDREN WITH CONGENITAL HEART DEFECTS

dc.contributor.author	Salomov Shoxabbos Nozimjon o’g’li
dc.contributor.author	Bustonov Sherzod
dc.date.accessioned	2025-12-29T11:30:28Z
dc.date.issued	2024-02-20
dc.description.abstract	193 vaccinated children were observed for 1.5 years. At the age of 2–6 months, 30% of premature and 46% of children with congenital heart defects were vaccinated with the PCV7/PCV13 vaccine; at the age of 7–11 months, 52 and 40%, respectively. In 65% of cases, the PCV7/PCV13 vaccine was administered together with other vaccines in the national preventive vaccination schedule. The frequency of general post-vaccination reactions (increase in body temperature from 37.6 to 38.0°C) was 4%; no local reactions were recorded. No other adverse events were noted in the post-vaccination period.
dc.format	application/pdf
dc.identifier.uri	https://americanjournal.org/index.php/ajtas/article/view/1869
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/17092
dc.language.iso	eng
dc.publisher	American Journals Publishing
dc.relation	https://americanjournal.org/index.php/ajtas/article/view/1869/1739
dc.rights	https://creativecommons.org/licenses/by-nc/4.0
dc.source	American Journal of Technology and Applied Sciences; Vol. 21 (2024); 37-39
dc.source	2832-1766
dc.title	PNEUMOCOCCAL VACCINE VACCINATION IN CHILDREN WITH CONGENITAL HEART DEFECTS
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: ogli_2024_pneumococcal_vaccine_vaccination_in_chil.pdf
item.page.filesection.size: 269.1 KB
item.page.filesection.format: Adobe Portable Document Format